Emma Cartmell

Emma is a Partner at Exsede Health Consulting where she helps innovative technology and services companies enter the healthcare market and grow. She also advises international investment banks on the Digital Health market. She founded the Austin HIMSS chapter in 2004, which was named "Chapter of the Year” in 2015; she currently serves on the board. Emma also serves as an advisor to Minister George Freeman on UK Trade and Investment in the US for Digital Health and Life Sciences.

Emma’s past experience includes serving as the Chief Operating Officer (COO) of NantHealth, a portfolio of technology and healthcare companies, where she oversaw acquisitions and investments as well as strategy and operations for over 50 companies. Prior to this role, Emma was the COO of Personalized Medicine at Abraxis BioScience where she was recruited to prepare the company for sale. Abraxis BioScience was a leading publicly traded oncology biotechnology company that was sold to Celgene in 2010 for $2.9 billion. Before Abraxis, Emma served as the Vice President of Healthcare Advanced Programs & Director of Health Business Development and Strategy at Science Applications International Corporation (SAIC) where she oversaw a $500M healthcare portfolio.

Emma currently advises growth stage companies, fortune 500’s and venture capital with a focus on value based care and innovation. Throughout her career she has mentored and promoted women in Digital Health. Emma has a Masters degree from King’s College London.